
South Africa Built a Medical Research Powerhouse. Trump Cuts Have Demolished It.
In the heart of Johannesburg, the lobby of a building that once housed hundreds of scientists is empty of people but choked with discarded office furniture and heaps of files hastily gathered from shuttered research sites.
South Africa has for decades been a medical research powerhouse, yet its stature has been little known to people outside the field. South Africa's scientists have been responsible for key breakthroughs against major global killers, including heart disease, H.I.V. and respiratory viruses such as Covid-19. They have worked closely with American researchers and have been awarded more research funding from the United States than any other country has received.
But a swift series of executive orders and budget cuts from the Trump administration have, in a matter of months, demolished this research ecosystem.
There are grim ramifications for human health worldwide, and also for pharmaceutical companies, including American giants such as Pfizer, Merck, Abbott and Gilead Sciences, which rely heavily on South Africa's research complex when they develop and test new drugs, vaccines and treatments.
'South Africa is the beacon,' said Dr. Harold Varmus, a professor of medicine at Cornell University who was awarded the Nobel Prize in medicine for his work on cancer biology and who was a director of the National Institutes of Health.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
3 hours ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Oneview Healthcare Chess Depository Interests repr 1 (OtherONVVF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Oneview Healthcare Chess Depository Interests repr 1 (ONVVF – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer (PFE) In a report released yesterday, Justin Smith from Bernstein maintained a Hold rating on Pfizer, with a price target of $30.00. The company's shares closed last Friday at $24.79, close to its 52-week low of $24.48. According to Smith is ranked #3539 out of 9922 analysts. Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $28.40, which is a 13.7% upside from current levels. In a report issued on July 22, TR | OpenAI – 4o also downgraded the stock to Hold with a $26.00 price target. In a report released yesterday, Martyn Jacobs from Bell Potter maintained a Buy rating on Oneview Healthcare Chess Depository Interests repr 1, with a price target of A$0.34. The company's shares closed last Friday at $0.16, equals to its 52-week high of $0.16. According to Jacobs is ranked #9692 out of 9922 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oneview Healthcare Chess Depository Interests repr 1 with a $0.23 average price target.


Bloomberg
7 hours ago
- Bloomberg
Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion
Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest levels in four years after GSK Plc agreed to pay $500 million upfront for the company's potential chronic lung disease treatment. The firm's Shanghai-listed stock rose as much as 8.16% to reach its highest level since July 2021, while its Hong Kong-listed shares were up as much as 10.95% on Monday.
Yahoo
16 hours ago
- Yahoo
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten